June 12, 2024 – Rutherrin® has been proven in preclinical studies to enhance the efficacy of chemotherapy and reduce multidrug resistance.
Ruvidar Enhances Efficacy of Cancer Drug
June 10, 2024 – Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation.
Theralase® Successfully Destroys Lung Cancer
June 6, 2024 – Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”).
Theralase® Technology Effective in Virus Inactivation
June 4, 2024 – Theralase’s lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with National Microbiology Laboratory and Theralase® Technologies Inc.
Theralase® Release’s 1Q2024 Financial Statements
May 30, 2024 – Theralase releases the Company’s unaudited interim consolidated 1Q2024 Financial Statements
Theralase® Expands Clinical Team
May 2, 2024 – Theralase expands its clinical team with the hiring of two Clinical Research Associates.
Theralase® Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024 – Theralase closes Non-Brokered Private Placement of units for gross proceeds of $CAN 750,200.
Theralase® Granted Canadian Cancer Vaccine Patent
April 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same”.
Theralase® Release’s 4Q2023 Interim Financial Statements
March 27, 2024 – Theralase released the Company’s audited annual consolidated 2023 financial statements (“Financial Statements”).
Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
V.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators (“PIs”) at the Canadian Urological Association (“CUA”) Bladder Cancer Forum and the American Urology Association (“AUA”), respectively. Study II is a Phase II clinical study that provides a Study Procedure (Study Drug activated by a Study Device) for patients diagnosed with Bacillus Calmette Guerin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”). An advisory board meeting is scheduled to take place on April 12, 2024, during the Bladder Cancer Forum 2024 located in … Read More